Clinical Trial News and Research

RSS

Personalized prehabilitation reduces the risk of surgical complications

The weeks leading up to a major surgery can be a time of uncertainty and worry for patients, many of whom anticipate the need for rehabilition to get back on their feet.

12 Nov 2025

Simple blood test may be a better guide treatment for ovarian cancer

More than 300,000 women are diagnosed with ovarian cancer globally each year.

12 Nov 2025

Common antibiotic can improve survival and neurological outcomes in CNS-TB

Researchers at the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine), have demonstrated that doxycycline, a commonly available and inexpensive antibiotic, can improve survival rates and neurological outcomes in Central Nervous System Tuberculosis (CNS-TB) in a preclinical non-human study.

12 Nov 2025

Self-guided hypnosis offers safe relief from menopausal hot flashes

Can a simple daily audio hypnosis session help women find relief from one of menopause's most disruptive symptoms – hot flashes – without medication? A new clinical trial led by Baylor University's Gary R. Elkins, Ph.D., professor of psychology and neuroscience and director of the Mind-Body Medicine Research Laboratory, suggests it can.

11 Nov 2025

AI repurposes routine CT scans to detect hidden bone loss

Computed tomography (CT) scans of the chest, abdomen, and spine, taken originally to detect problems such as kidney stones or growths on the lungs, can be repurposed through artificial intelligence (AI) to catch signs of bone loss, a new study shows.

11 Nov 2025

Long non-coding RNA MALAT1 linked to progression and spread of triple-negative breast cancer

When researchers look for potential cancer therapy targets, they typically go after protein-coding genes that participate in disease progression. Disrupt them and negate whatever role they play in cancer's development or spread.

11 Nov 2025

Tailored vitamin D regimens offer significant cardiac benefit

Adults with heart disease who had a previous heart attack and took vitamin D doses tailored to reach optimal blood levels reduced their risk of another heart attack by more than half compared to those who did not have their vitamin D blood levels optimized, according to a preliminary study to be presented at the American Heart Association's Scientific Sessions 2025.

11 Nov 2025

New data supports earlier use of evolocumab in high-risk diabetes

Adding the PCSK9 inhibitor evolocumab to a high-intensity, cholesterol-lowering regimen reduced the risk of a first major cardiovascular event among adults with atherosclerotic cardiovascular disease (ASCVD) or diabetes , according to a preliminary late-breaking science presentation today at the American Heart Association's Scientific Sessions 2025.

11 Nov 2025

Novel triple receptor agonist shows potent efficacy in lowering high triglycerides

In a small, short duration trial (12 weeks), a new medication called DR10624 reduced triglyceride levels in most patients with severe hypertriglyceridemia by more than 60%, according to a preliminary late-breaking science presentation today at the American Heart Association's Scientific Sessions 2025.

11 Nov 2025

St. Jude study maps treatment strategy for rare infant gliomas

Clinician-scientists at St. Jude Children's Research Hospital and collaborators have conducted the largest study of infant-type hemispheric glioma (IHG) ever reported, uncovering key factors that could be used to guide treatment strategies for this rare pediatric brain tumor.

11 Nov 2025

Researchers achieve long-term remission with novel T cell therapies for HPV-related cancers

Researchers from Rutgers Cancer Institute, New Jersey's only National Cancer Institute (NCI) - designated Comprehensive Cancer Center, and RWJBarnabas Health, along with colleagues from the National Cancer Institute, a center of the National Institutes of Health, announced findings from two HPV-related studies that highlight the potential of novel T cell therapies to achieve long-lasting remission and complete tumor regression in patients with advanced epithelial cancers.

10 Nov 2025

Comparative study finds higher rates of adverse events with ticagrelor

One year of treatment with either of two strong blood-thinning medications—ticagrelor and prasugrel—by people with type 1 or type 2 diabetes who had a drug-eluting stent placed in their heart to treat coronary artery blockages did not offer the same level of benefit to prevent stent clotting, heart attacks, and bleeding complications, according to findings presented during a preliminary late-breaking science session during the American Heart Association's Scientific Sessions 2025 in New Orleans on November 10.

10 Nov 2025

Clinical trial confirms ivermectin safety in very young children down to 5 kg

Millions of very young children currently excluded from treatment with the drug ivermectin could be safely included in ongoing campaigns against challenging and often neglected tropical diseases such as intestinal worms, scabies and river blindness, according to results from a clinical trial presented today at the Annual Meeting of the American Society of Tropical Medicine and Hygiene (ASTMH).

10 Nov 2025

Prasugrel shows advantage over ticagrelor in diabetic patients after stent placement

One year of dual antiplatelet therapy with one of two potent P2Y12 inhibitors-ticagrelor or prasugrel-in people with Type 1 or Type 2 diabetes who had received a drug-eluting stent did not offer the same level of benefit at preventing stent clotting, heart attacks and bleeding complications, according to a preliminary late-breaking science presentation today at the American Heart Association's Scientific Sessions 2025.

10 Nov 2025

New drug combination gains Fast Track Designation for metastatic colorectal cancer

The U.S. Food and Drug Administration has granted Fast Track Designation to a new drug combination for metastatic colorectal cancer, following encouraging results from a clinical trial led in part by the University of Oklahoma Health Stephenson Cancer Center.

10 Nov 2025

PCSK9 inhibitor combined with a statin may help reduce LDL cholesterol after heart transplant

The cholesterol medication alirocumab, a PCSK9 inhibitor, combined with a statin appeared to reduce LDL cholesterol levels by more than 50% among patients after a heart transplant, according to a late-breaking science presentation today at the American Heart Association's Scientific Sessions 2025.

10 Nov 2025

One cup of coffee a day could keep atrial fibrillation from coming back

A multicenter randomized clinical trial found that moderate caffeinated coffee intake after cardioversion significantly lowered the recurrence of atrial fibrillation or flutter compared with abstinence. The findings challenge long-standing advice to avoid coffee in cardiac arrhythmia patients and support its safety at typical consumption levels.

10 Nov 2025